One-year findings from B Braun’s CONSEQUENT ALL COMERS observational study were recently published by principal investigator Ralf Langhoff (Sankt Gertrauden Hospital, Berlin, Germany) et al online in Angiology. The data were first presented earlier this year at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online).
In this prospective, single-arm, multicentre observational study, the SeQuent Please over-the-wire (OTW) drug-coated balloon (DCB; B Braun) was used in above-the-knee (ATK) and below-the-knee (BTK) peripheral arterial occlusive disease. The investigators report that, despite the high prevalence of comorbidities, target lesion revascularisation (TLR) and mortality rates were comparable for clinical outcomes of other contemporary DCBs.
Langhoff and colleagues detail that the overall technical success rate of the 1,269 DCBs used was 99.6% (1.6±0.79 DCBs/patient), adding that 12-month TLR rates were 6.3% in patients with chronic limb-threatening ischaemia (CLTI) and 9.6% in claudicants, with a primary patency rate of 89.9% and 87.1%, respectively. They also write that all-cause mortality was 4.3%.